Apollomics Inc. - Class A Ordinary Shares (APLM)
20.99
+1.49 (7.64%)
NASDAQ · Last Trade: Oct 16th, 9:53 AM EDT
Via Benzinga · October 16, 2025
The stock fell after-hours even after Nasdaq confirmed the biotech had regained compliance with listing standards.
Via Stocktwits · October 16, 2025
Via Benzinga · October 15, 2025
Via Benzinga · September 17, 2025
Via Benzinga · September 16, 2025
Via Benzinga · September 16, 2025
Via Benzinga · September 3, 2025
Via Benzinga · August 28, 2025
Via Benzinga · August 28, 2025
Via Benzinga · July 24, 2025
Via Benzinga · July 9, 2025
Via Benzinga · June 18, 2025
Via Benzinga · June 13, 2025
Via Benzinga · May 21, 2025
Via Benzinga · March 31, 2025

Via Benzinga · November 20, 2024

Via Benzinga · November 19, 2024

Via Benzinga · November 18, 2024

Via Benzinga · November 18, 2024

Via Benzinga · September 30, 2024

Apollomics shares soared after revealing promising Phase 2 SPARTA trial data for vebreltinib in non-CNS MET fusion solid tumors, showing a 43% ORR with notable responses in metastatic NSCLC, pancreatic, and bile duct cancers.
Via Benzinga · August 13, 2024